High-sensitivity C-reactive protein in every chart? The use of biomarkers in individual patients

Area of Science:

• Cardiology
• Biomarkers
• Metabolic Syndrome

Background:

• Epidemiologic evidence supports high-sensitivity C-reactive protein (hsCRP) for cardiovascular disease risk stratification.
• The clinical utility of hsCRP remains a subject of ongoing debate and controversy.
• Elevated hsCRP is often associated with a specific metabolic environment.

Purpose of the Study:

• To critically assess the evidence supporting the use of hsCRP in clinical practice.
• To provide a framework for understanding hsCRP's role and limitations.
• To examine the relationship between hsCRP, abdominal obesity, and insulin resistance.

Main Methods:

• Critical review and assessment of existing epidemiologic and clinical data.
• Analysis of the metabolic context (abdominal obesity, insulin resistance) influencing hsCRP levels.
• Evaluation of the strengths and limitations of hsCRP as a cardiovascular risk marker.

Main Results:

• hsCRP's association with cardiovascular disease is supported by substantial epidemiologic data.
• The metabolic milieu, including abdominal obesity and insulin resistance, provides context for hsCRP elevation.
• Limitations of hsCRP use in clinical practice are highlighted.

Conclusions:

• While epidemiologic data support hsCRP's role, its controversial status necessitates careful interpretation.
• Understanding the interplay between hsCRP, metabolic factors, and cardiovascular risk is crucial.
• Further critical assessment is needed to define hsCRP's definitive place in clinical practice.